Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

PURPOSE: Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Choueiri, Toni K., Halabi, Susan, Sanford, Ben L., Hahn, Olwen, Michaelson, M. Dror, Walsh, Meghara K., Feldman, Darren R., Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, George, Daniel J., Morris, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455807/
https://ncbi.nlm.nih.gov/pubmed/28199818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.7398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados